1
|
Olson ND, Wagner J, McDaniel J, Stephens SH, Westreich ST, Prasanna AG, Johanson E, Boja E, Maier EJ, Serang O, Jáspez D, Lorenzo-Salazar JM, Muñoz-Barrera A, Rubio-Rodríguez LA, Flores C, Kyriakidis K, Malousi A, Shafin K, Pesout T, Jain M, Paten B, Chang PC, Kolesnikov A, Nattestad M, Baid G, Goel S, Yang H, Carroll A, Eveleigh R, Bourgey M, Bourque G, Li G, Ma C, Tang L, Du Y, Zhang S, Morata J, Tonda R, Parra G, Trotta JR, Brueffer C, Demirkaya-Budak S, Kabakci-Zorlu D, Turgut D, Kalay Ö, Budak G, Narcı K, Arslan E, Brown R, Johnson IJ, Dolgoborodov A, Semenyuk V, Jain A, Tetikol HS, Jain V, Ruehle M, Lajoie B, Roddey C, Catreux S, Mehio R, Ahsan MU, Liu Q, Wang K, Ebrahim Sahraeian SM, Fang LT, Mohiyuddin M, Hung C, Jain C, Feng H, Li Z, Chen L, Sedlazeck FJ, Zook JM. PrecisionFDA Truth Challenge V2: Calling variants from short and long reads in difficult-to-map regions. Cell Genom 2022; 2:S2666-979X(22)00058-1. [PMID: 35720974 PMCID: PMC9205427 DOI: 10.1016/j.xgen.2022.100129] [Citation(s) in RCA: 48] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Revised: 11/01/2021] [Accepted: 04/08/2022] [Indexed: 11/19/2022]
Abstract
The precisionFDA Truth Challenge V2 aimed to assess the state of the art of variant calling in challenging genomic regions. Starting with FASTQs, 20 challenge participants applied their variant-calling pipelines and submitted 64 variant call sets for one or more sequencing technologies (Illumina, PacBio HiFi, and Oxford Nanopore Technologies). Submissions were evaluated following best practices for benchmarking small variants with updated Genome in a Bottle benchmark sets and genome stratifications. Challenge submissions included numerous innovative methods, with graph-based and machine learning methods scoring best for short-read and long-read datasets, respectively. With machine learning approaches, combining multiple sequencing technologies performed particularly well. Recent developments in sequencing and variant calling have enabled benchmarking variants in challenging genomic regions, paving the way for the identification of previously unknown clinically relevant variants.
Collapse
Affiliation(s)
- Nathan D. Olson
- Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Dr, MS8312, Gaithersburg, MD 20899, USA
| | - Justin Wagner
- Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Dr, MS8312, Gaithersburg, MD 20899, USA
| | - Jennifer McDaniel
- Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Dr, MS8312, Gaithersburg, MD 20899, USA
| | | | | | | | - Elaine Johanson
- Office of Health Informatics, Office of the Chief Scientist, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA
| | - Emily Boja
- Office of Health Informatics, Office of the Chief Scientist, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA
| | - Ezekiel J. Maier
- Booz Allen Hamilton, 8283 Greensboro Drive, Mclean, VA 22102, USA
| | - Omar Serang
- DNAnexus, Inc., 1975 W El Camino Real #204, Mountain View, CA 94040, USA
| | - David Jáspez
- Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain
| | - José M. Lorenzo-Salazar
- Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain
| | - Adrián Muñoz-Barrera
- Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain
| | - Luis A. Rubio-Rodríguez
- Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain
| | - Carlos Flores
- Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain
- CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
- Research Unit, Hospital Universitario N.S. de Candelaria, Santa Cruz de Tenerife, Spain
- Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, 38200 San Cristóbal de La Laguna, Spain
| | - Konstantinos Kyriakidis
- School of Pharmacy, Aristotle University of Thessaloniki (AUTH), 541 24 Thessaloniki, Greece
- Genomics and Epigenomics Translational Research (GENeTres), Center for Interdisciplinary Research and Innovation, 570 01 Thessaloniki, Greece
| | - Andigoni Malousi
- Genomics and Epigenomics Translational Research (GENeTres), Center for Interdisciplinary Research and Innovation, 570 01 Thessaloniki, Greece
- Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki (AUTH), 541 24 Thessaloniki, Greece
| | - Kishwar Shafin
- UC Santa Cruz Genomics Institute, University of California, Santa Cruz, 1156 High Street, Santa Cruz, CA, USA
| | - Trevor Pesout
- UC Santa Cruz Genomics Institute, University of California, Santa Cruz, 1156 High Street, Santa Cruz, CA, USA
| | - Miten Jain
- UC Santa Cruz Genomics Institute, University of California, Santa Cruz, 1156 High Street, Santa Cruz, CA, USA
| | - Benedict Paten
- UC Santa Cruz Genomics Institute, University of California, Santa Cruz, 1156 High Street, Santa Cruz, CA, USA
| | - Pi-Chuan Chang
- Google Inc, 1600 Amphitheater Pkwy, Mountain View, CA 94040, USA
| | | | - Maria Nattestad
- Google Inc, 1600 Amphitheater Pkwy, Mountain View, CA 94040, USA
| | - Gunjan Baid
- Google Inc, 1600 Amphitheater Pkwy, Mountain View, CA 94040, USA
| | - Sidharth Goel
- Google Inc, 1600 Amphitheater Pkwy, Mountain View, CA 94040, USA
| | - Howard Yang
- Google Inc, 1600 Amphitheater Pkwy, Mountain View, CA 94040, USA
| | - Andrew Carroll
- Google Inc, 1600 Amphitheater Pkwy, Mountain View, CA 94040, USA
| | - Robert Eveleigh
- The Canadian Center for Computational Genomics (C3G), Montréal, QC, Canada
| | - Mathieu Bourgey
- The Canadian Center for Computational Genomics (C3G), Montréal, QC, Canada
| | - Guillaume Bourque
- The Canadian Center for Computational Genomics (C3G), Montréal, QC, Canada
| | - Gen Li
- HuXinDao, QingZhuHu TaiYangShan Road, KaiFu, ChangSha, HuNan, China
| | - ChouXian Ma
- HuXinDao, QingZhuHu TaiYangShan Road, KaiFu, ChangSha, HuNan, China
| | - LinQi Tang
- HuXinDao, QingZhuHu TaiYangShan Road, KaiFu, ChangSha, HuNan, China
| | - YuanPing Du
- HuXinDao, QingZhuHu TaiYangShan Road, KaiFu, ChangSha, HuNan, China
| | - ShaoWei Zhang
- HuXinDao, QingZhuHu TaiYangShan Road, KaiFu, ChangSha, HuNan, China
| | - Jordi Morata
- CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 4, 08028 Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Raúl Tonda
- CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 4, 08028 Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Genís Parra
- CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 4, 08028 Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Jean-Rémi Trotta
- CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 4, 08028 Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Christian Brueffer
- Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | | | | | - Deniz Turgut
- Seven Bridges Genomics, Inc, Charlestown, MA, USA
| | - Özem Kalay
- Seven Bridges Genomics, Inc, Charlestown, MA, USA
| | - Gungor Budak
- Seven Bridges Genomics, Inc, Charlestown, MA, USA
| | - Kübra Narcı
- Seven Bridges Genomics, Inc, Charlestown, MA, USA
| | - Elif Arslan
- Seven Bridges Genomics, Inc, Charlestown, MA, USA
| | | | | | | | | | - Amit Jain
- Seven Bridges Genomics, Inc, Charlestown, MA, USA
| | | | | | | | | | | | | | | | - Mian Umair Ahsan
- Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Qian Liu
- Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Kai Wang
- Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | | | - Li Tai Fang
- Roche Sequencing Solutions, Santa Clara, CA 95050, USA
| | | | | | - Chirag Jain
- National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | | | | | | | - Fritz J. Sedlazeck
- Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
| | - Justin M. Zook
- Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Dr, MS8312, Gaithersburg, MD 20899, USA
| |
Collapse
|
2
|
Zhang L, Evans DS, Raheja UK, Stephens SH, Stiller JW, Reeves G, Johnson M, Ryan KA, Weizel N, Vaswani D, McLain H, Shuldiner AR, Mitchell BD, Hsueh WC, Snitker S, Postolache TT. Chronotype and seasonality: morningness is associated with lower seasonal mood and behavior changes in the Old Order Amish. J Affect Disord 2015; 174:209-14. [PMID: 25527990 PMCID: PMC4356625 DOI: 10.1016/j.jad.2014.11.039] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Accepted: 11/20/2014] [Indexed: 12/13/2022]
Abstract
BACKGROUND Several studies documented that lower scores on the Morningness-Eveningness Questionnaire (MEQ) are associated with a higher global seasonality of mood (GSS). As for the Modern Man artificial lighting predominantly extends evening activity and exposure to light, and as evening bright light phase is known to delay circadian rhythms, this chronic exposure could potentially lead to both lower Morningness as well as higher GSS. The aim of the study was to investigate if the MEQ-GSS relationship holds in the Old Order Amish of Lancaster County, PA, a population that does not use network electrical light. METHODS 489 Old Order Amish adults (47.6% women), with average (SD) age of 49.7 (14.2) years, completed both the Seasonal Pattern Assessment Questionnaire (SPAQ) for the assessment of GSS, and MEQ. Associations between GSS scores and MEQ scores were analyzed using linear models, accounting for age, gender and relatedness by including the relationship matrix in the model as a random effect. RESULTS GSS was inversely associated with MEQ scores (p=0.006, adjusted). LIMITATIONS include a potential recall bias associated with self-report questionnaires and no actual light exposure measurements. CONCLUSION We confirmed the previously reported inverse association between MEQ scores and lower seasonality of mood, for the first time in a population that does not use home network electrical lighting. This result suggests that the association is not a byproduct of exposure to network electric light, and calls for additional research to investigate mechanisms by which Morningness is negatively associated with seasonality.
Collapse
Affiliation(s)
- Layan Zhang
- Mood and Anxiety Program, University of Maryland School of Medicine,
Baltimore, MD, USA,Saint Elizabeths Hospital, Psychiatry Residency Training Program,
Washington, DC, USA
| | - Daniel S. Evans
- California Pacific Medical Center Research Institute, San Francisco,
CA, USA
| | - Uttam K. Raheja
- Mood and Anxiety Program, University of Maryland School of Medicine,
Baltimore, MD, USA,Saint Elizabeths Hospital, Psychiatry Residency Training Program,
Washington, DC, USA
| | - Sarah H. Stephens
- Division of Endocrinology, Diabetes and Nutrition, Department of
Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - John W. Stiller
- Mood and Anxiety Program, University of Maryland School of Medicine,
Baltimore, MD, USA,Saint Elizabeths Hospital, Psychiatry Residency Training Program,
Washington, DC, USA
| | - Gloria Reeves
- Division of Child and Adolescent Psychiatry & University of
Maryland Child and Adolescent Mental Health Innovations Center, University of
Maryland School of Medicine, Baltimore, MD, USA
| | - Mary Johnson
- Department of Ophthalmology & Visual Sciences, University of
Maryland School of Medicine, Baltimore, MD
| | - Kathleen A Ryan
- Division of Endocrinology, Diabetes and Nutrition, Department of
Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Nancy Weizel
- Division of Child and Adolescent Psychiatry & University of
Maryland Child and Adolescent Mental Health Innovations Center, University of
Maryland School of Medicine, Baltimore, MD, USA
| | - Dipika Vaswani
- Mood and Anxiety Program, University of Maryland School of Medicine,
Baltimore, MD, USA
| | - Hassan McLain
- Mood and Anxiety Program, University of Maryland School of Medicine,
Baltimore, MD, USA
| | - Alan R. Shuldiner
- Division of Endocrinology, Diabetes and Nutrition, Department of
Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Braxton D. Mitchell
- Division of Endocrinology, Diabetes and Nutrition, Department of
Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Wen-Chi Hsueh
- Phoenix Epidemiology and Clinical Research Branch, NIDDK, National
Institutes of Health, Phoenix, AZ
| | - Soren Snitker
- Division of Endocrinology, Diabetes and Nutrition, Department of
Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Teodor T. Postolache
- Mood and Anxiety Program, University of Maryland School of Medicine,
Baltimore, MD, USA,VISN 5 Capitol Health Care Network Mental Illness Research Education
and Clinical Center (MIRECC), Baltimore, MD, USA and VISN 19 MIRECC, Denver,
Colorado, USA,Corresponding author at: University of Maryland School
of Medicine, Mood and Anxiety Program, Department of Psychiatry, 685 West
Baltimore Street, MSTF Building Room 930, Baltimore, MD 21201, USA., Tel.:
+1 4107062323; fax: +1 4107060751.,
(T.T. Postolache)
| |
Collapse
|
3
|
Byrne EM, Raheja U, Stephens SH, Heath AC, Madden PAF, Vaswani D, Nijjar GV, Ryan KA, Youssufi H, Gehrman PR, Shuldiner AR, Martin NG, Montgomery GW, Wray NR, Nelson EC, Mitchell BD, Postolache TT. Seasonality shows evidence for polygenic architecture and genetic correlation with schizophrenia and bipolar disorder. J Clin Psychiatry 2015; 76:128-34. [PMID: 25562672 PMCID: PMC4527536 DOI: 10.4088/jcp.14m08981] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2014] [Accepted: 08/29/2014] [Indexed: 01/17/2023]
Abstract
OBJECTIVE To test common genetic variants for association with seasonality (seasonal changes in mood and behavior) and to investigate whether there are shared genetic risk factors between psychiatric disorders and seasonality. METHOD Genome-wide association studies (GWASs) were conducted in Australian (between 1988 and 1990 and between 2010 and 2013) and Amish (between May 2010 and December 2011) samples in whom the Seasonal Pattern Assessment Questionnaire (SPAQ) had been administered, and the results were meta-analyzed in a total sample of 4,156 individuals. Genetic risk scores based on results from prior large GWAS studies of bipolar disorder, major depressive disorder (MDD), and schizophrenia were calculated to test for overlap in risk between psychiatric disorders and seasonality. RESULTS The most significant association was with rs11825064 (P = 1.7 × 10⁻⁶, β = 0.64, standard error = 0.13), an intergenic single nucleotide polymorphism (SNP) found on chromosome 11. The evidence for overlap in risk factors was strongest for schizophrenia and seasonality, with the schizophrenia genetic profile scores explaining 3% of the variance in log-transformed global seasonality scores. Bipolar disorder genetic profile scores were also associated with seasonality, although at much weaker levels (minimum P value = 3.4 × 10⁻³), and no evidence for overlap in risk was detected between MDD and seasonality. CONCLUSIONS Common SNPs of large effect most likely do not exist for seasonality in the populations examined. As expected, there were overlapping genetic risk factors for bipolar disorder (but not MDD) with seasonality. Unexpectedly, the risk for schizophrenia and seasonality had the largest overlap, an unprecedented finding that requires replication in other populations and has potential clinical implications considering overlapping cognitive deficits in seasonal affective disorders and schizophrenia.
Collapse
Affiliation(s)
- Enda M Byrne
- The University of Queensland, Queensland Brain Institute, Upland Rd, St Lucia, QLD 4072, Brisbane, Australia
| | - Uttam Raheja
- Mood and Anxiety Program, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA,Saint Elizabeths Hospital, Psychiatry Residency Training Program, Washington, DC, USA
| | - Sarah H. Stephens
- Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Andrew C Heath
- Department of Psychiatry, Washington University, St.Louis, MO, USA
| | - Pamela AF Madden
- Department of Psychiatry, Washington University, St.Louis, MO, USA
| | | | - Dipika Vaswani
- Mood and Anxiety Program, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | - Gagan V. Nijjar
- Mood and Anxiety Program, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA,Department of Psychiatry, Kaiser Permanente, Santa Rosa CA
| | - Kathleen A. Ryan
- Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Hassaan Youssufi
- Mood and Anxiety Program, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | - Philip R Gehrman
- Behavioral Sleep Medicine Program, Department of Psychiatry & Penn Sleep Center, University of Pennsylvania, Philadelphia, USA
| | - Alan R Shuldiner
- Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA,Geriatric Research and Education Clinical Center, Veterans Administration Medical Center, Baltimore, MD, USA
| | - Nicholas G Martin
- Queensland Institute of Medical Research, 300 Herston Road, Herston, QLD 4029
| | - Grant W Montgomery
- Queensland Institute of Medical Research, 300 Herston Road, Herston, QLD 4029
| | - Naomi R Wray
- The University of Queensland, Queensland Brain Institute, St. Lucia, QLD 4072, Australia
| | - Elliot C Nelson
- Department of Psychiatry, Washington University, St.Louis, MO, USA
| | - Braxton D Mitchell
- Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA,Geriatric Research and Education Clinical Center, Veterans Administration Medical Center, Baltimore, MD, USA
| | - Teodor T Postolache
- Mood and Anxiety Program, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA,Saint Elizabeths Hospital, Psychiatry Residency Training Program, Washington, DC, USA,Division of Child and Adolescent Psychiatry & University of Maryland Child and Adolescent Mental Health Innovations Center, University of Maryland School of Medicine, Baltimore, MD, USA,National Center for the Treatment of Phobias, Anxiety and Depression, Washington, DC, USA
| |
Collapse
|
4
|
Melroy WE, Stephens SH, Sakai JT, Kamens HM, McQueen MB, Corley RP, Stallings MC, Hopfer CJ, Krauter KS, Brown SA, Hewitt JK, Ehringer MA. Examination of genetic variation in GABRA2 with conduct disorder and alcohol abuse and dependence in a longitudinal study. Behav Genet 2014; 44:356-67. [PMID: 24687270 DOI: 10.1007/s10519-014-9653-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Accepted: 03/15/2014] [Indexed: 02/06/2023]
Abstract
Previous studies have shown associations between single nucleotide polymorphisms (SNPs) in gamma aminobutyric acid receptor alpha 2 (GABRA2) and adolescent conduct disorder (CD) and alcohol dependence in adulthood, but not adolescent alcohol dependence. The present study was intended as a replication and extension of this work, focusing on adolescent CD, adolescent alcohol abuse and dependence (AAD), and adult AAD. Family based association tests were run using Hispanics and non-Hispanic European American subjects from two independent longitudinal samples. Although the analysis provided nominal support for an association with rs9291283 and AAD in adulthood and CD in adolescence, the current study failed to replicate previous associations between two well replicated GABRA2 SNPs and CD and alcohol dependence. Overall, these results emphasize the utility of including an independent replication sample in the study design, so that the results from an individual sample can be weighted in the context of its reproducibility.
Collapse
Affiliation(s)
- Whitney E Melroy
- Institute for Behavioral Genetics, University of Colorado, Boulder, CO, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Nugent KL, Million-Mrkva A, Backman J, Stephens SH, Reed RM, Kochunov P, Pollin TI, Shuldiner AR, Mitchell BD, Hong LE. Familial aggregation of tobacco use behaviors among Amish men. Nicotine Tob Res 2014; 16:923-30. [PMID: 24583363 DOI: 10.1093/ntr/ntu006] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
INTRODUCTION Tobacco use is a complex behavior. The Old Order Amish community offers unique advantages for the study of tobacco use because of homogenous ancestral background, sociocultural similarity, sex-specific social norms regarding tobacco use, and large family size. Tobacco use in the Old Order Amish community is almost exclusively confined to males. METHODS We examined characteristics of tobacco use and familial aggregation among 1,216 Amish males from cross-sectional prospectively collected data. Outcomes examined included ever using tobacco regularly, current use, quantity of use, duration of use, and frequency of use. RESULTS Sixteen percent of Amish men were current tobacco users, with the majority reporting cigar use only. Higher rates of tobacco use were found among sons of fathers who smoked compared with sons of fathers who did not smoke (46% vs. 22%, p < .001) as well as among brothers of index cases who smoked compared with brothers of index cases who did not smoke (61% vs. 29%, p < .001). After controlling for shared household effects and age, heritability accounted for 66% of the variance in ever smoking regularly (p = .045). CONCLUSIONS The familial patterns of tobacco use observed among Amish men highlight the important role of family in propagating tobacco use and support the usefulness of this population for future genetic studies of nicotine addiction.
Collapse
Affiliation(s)
- Katie L Nugent
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD;
| | - Amber Million-Mrkva
- Graduate Program in Epidemiology and Human Genetics, University of Maryland, Baltimore, MD
| | - Joshua Backman
- Graduate Program in Epidemiology and Human Genetics, University of Maryland, Baltimore, MD
| | - Sarah H Stephens
- Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD
| | - Robert M Reed
- Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD
| | - Peter Kochunov
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD
| | - Toni I Pollin
- Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD
| | - Alan R Shuldiner
- Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD
| | - Braxton D Mitchell
- Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD; Department of Veterans Affairs, Veterans Affairs Medical Center, Baltimore Geriatric Research Education and Clinical Center, Baltimore, MD
| | - L Elliot Hong
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD
| |
Collapse
|
6
|
Stephens SH, Hartz SM, Hoft NR, Saccone NL, Corley RC, Hewitt JK, Hopfer CJ, Breslau N, Coon H, Chen X, Ducci F, Dueker N, Franceschini N, Frank J, Han Y, Hansel NN, Jiang C, Korhonen T, Lind PA, Liu J, Lyytikäinen LP, Michel M, Shaffer JR, Short SE, Sun J, Teumer A, Thompson JR, Vogelzangs N, Vink JM, Wenzlaff A, Wheeler W, Yang BZ, Aggen SH, Balmforth AJ, Baumeister SE, Beaty TH, Benjamin DJ, Bergen AW, Broms U, Cesarini D, Chatterjee N, Chen J, Cheng YC, Cichon S, Couper D, Cucca F, Dick D, Foroud T, Furberg H, Giegling I, Gillespie NA, Gu F, Hall AS, Hällfors J, Han S, Hartmann AM, Heikkilä K, Hickie IB, Hottenga JJ, Jousilahti P, Kaakinen M, Kähönen M, Koellinger PD, Kittner S, Konte B, Landi MT, Laatikainen T, Leppert M, Levy SM, Mathias RA, McNeil DW, Medland SE, Montgomery GW, Murray T, Nauck M, North KE, Paré PD, Pergadia M, Ruczinski I, Salomaa V, Viikari J, Willemsen G, Barnes KC, Boerwinkle E, Boomsma DI, Caporaso N, Edenberg HJ, Francks C, Gelernter J, Grabe HJ, Hops H, Jarvelin MR, Johannesson M, Kendler KS, Lehtimäki T, Magnusson PK, Marazita ML, Marchini J, Mitchell BD, Nöthen MM, Penninx BW, Raitakari O, Rietschel M, Rujescu D, Samani NJ, Schwartz AG, Shete S, Spitz M, Swan GE, Völzke H, Veijola J, Wei Q, Amos C, Cannon DS, Grucza R, Hatsukami D, Heath A, Johnson EO, Kaprio J, Madden P, Martin NG, Stevens VL, Weiss RB, Kraft P, Bierut LJ, Ehringer MA. Distinct loci in the CHRNA5/CHRNA3/CHRNB4 gene cluster are associated with onset of regular smoking. Genet Epidemiol 2013; 37:846-59. [PMID: 24186853 PMCID: PMC3947535 DOI: 10.1002/gepi.21760] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Revised: 06/21/2013] [Accepted: 08/14/2013] [Indexed: 12/21/2022]
Abstract
Neuronal nicotinic acetylcholine receptor (nAChR) genes (CHRNA5/CHRNA3/CHRNB4) have been reproducibly associated with nicotine dependence, smoking behaviors, and lung cancer risk. Of the few reports that have focused on early smoking behaviors, association results have been mixed. This meta-analysis examines early smoking phenotypes and SNPs in the gene cluster to determine: (1) whether the most robust association signal in this region (rs16969968) for other smoking behaviors is also associated with early behaviors, and/or (2) if additional statistically independent signals are important in early smoking. We focused on two phenotypes: age of tobacco initiation (AOI) and age of first regular tobacco use (AOS). This study included 56,034 subjects (41 groups) spanning nine countries and evaluated five SNPs including rs1948, rs16969968, rs578776, rs588765, and rs684513. Each dataset was analyzed using a centrally generated script. Meta-analyses were conducted from summary statistics. AOS yielded significant associations with SNPs rs578776 (beta = 0.02, P = 0.004), rs1948 (beta = 0.023, P = 0.018), and rs684513 (beta = 0.032, P = 0.017), indicating protective effects. There were no significant associations for the AOI phenotype. Importantly, rs16969968, the most replicated signal in this region for nicotine dependence, cigarettes per day, and cotinine levels, was not associated with AOI (P = 0.59) or AOS (P = 0.92). These results provide important insight into the complexity of smoking behavior phenotypes, and suggest that association signals in the CHRNA5/A3/B4 gene cluster affecting early smoking behaviors may be different from those affecting the mature nicotine dependence phenotype.
Collapse
Affiliation(s)
- Sarah H. Stephens
- Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland, United States of America
| | - Sarah M. Hartz
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Nicole R. Hoft
- Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado, United States of America
| | - Nancy L. Saccone
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Robin C. Corley
- Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado, United States of America
| | - John K. Hewitt
- Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado, United States of America
| | - Christian J. Hopfer
- Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado, United States of America
| | - Naomi Breslau
- Department of Epidemiology, Michigan State University, East Lansing, Michigan, United States of America
| | - Hilary Coon
- Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah, United States of America
| | - Xiangning Chen
- Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States of America
| | - Francesca Ducci
- Institute of Psychiatry, King’s College London and Department of Mental Health, St George’s University, London, United Kingdom
- Department of Psychiatry, Neurobiology, Pharmacology, and Biotechnology, University of Pisa, Pisa, Italy
| | - Nicole Dueker
- Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland, United States of America
| | - Nora Franceschini
- Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, United States of America
| | - Josef Frank
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Clinical Faculty Mannheim / Heidelberg University, Mannheim, Germany
| | - Younghun Han
- Department of Epidemiology, MD Anderson, Houston, Texas, United States of America
| | - Nadia N. Hansel
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
| | - Chenhui Jiang
- Departments of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America
| | - Tellervo Korhonen
- Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki, Finland
| | - Penelope A. Lind
- Department of Epidemiology, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
| | - Jason Liu
- Department of Statistics, University of Oxford, Oxford, United Kingdom
| | - Leo-Pekka Lyytikäinen
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere University Hospital and University of Tampere School of Medicine, Tampere, Finland
| | - Martha Michel
- Center for Health Sciences, SRI International, Menlo Park, California, United States of America
| | - John R. Shaffer
- Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| | - Susan E. Short
- Department of Sociology, Brown University, Providence, Rhode Island, United States of America
| | - Juzhong Sun
- Department of Epidemiology Research, American Cancer Society, Atlanta, Georgia, United States of America
| | - Alexander Teumer
- University Medicine Greifswald, University of Greifswald, Greifswald, Germany
| | - John R. Thompson
- Department of Health Sciences, University of Leicester, Leicester, United Kingdom
| | - Nicole Vogelzangs
- Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands
| | - Jacqueline M. Vink
- Department of Biological Psychology, VU University, Amsterdam, Amsterdam, The Netherlands
| | - Angela Wenzlaff
- Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States of America
| | - William Wheeler
- Division of Cancer Epidemiology and Genetics, National Institute of Health, Bethesda, Maryland, United States of America
| | - Bao-Zhu Yang
- Departments of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America
| | - Steven H. Aggen
- Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States of America
| | - Anthony J. Balmforth
- LIGHT Research Institute, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom
| | | | - Terri H. Beaty
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
| | - Daniel J. Benjamin
- Department of Economics, Cornell University, Ithaca, New York, United States of America
| | - Andrew W. Bergen
- Center for Health Sciences, SRI International, Menlo Park, California, United States of America
| | - Ulla Broms
- Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki, Finland
| | - David Cesarini
- Department of Economics, New York University, New York, New York, United States of America
| | - Nilanjan Chatterjee
- Division of Cancer Epidemiology and Genetics, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Jingchun Chen
- Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States of America
| | - Yu-Ching Cheng
- Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland, United States of America
| | - Sven Cichon
- Institute of Neuroscience and Medicine (INM-1); Structural and Functional Organization of the Brain Genomic Imaging; Department of Genomics, Life and Brain Center; Research Center Juelich, Juelich, Germany; Life and Brain Center and Institute of Human Genetics, University of Bonn, Bonn, Germany
| | - David Couper
- Department of Psychiatry, Neurobiology, Pharmacology, and Biotechnology, University of Pisa, Pisa, Italy
| | - Francesco Cucca
- Istituto di Ricerca Genetica e Biomedica, CNR, Cittadella Universitaria di Monserrato, Monserrato, Cagliari, Italy
| | - Danielle Dick
- Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States of America
| | - Tatiana Foroud
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
| | - Helena Furberg
- Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
| | - Ina Giegling
- Department of Psychiatry, University of Munich (LMU), Munich, Germany
| | - Nathan A. Gillespie
- Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States of America
| | - Fangyi Gu
- Division of Cancer Epidemiology and Genetics, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Alistair S. Hall
- LIGHT Research Institute, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom
| | - Jenni Hällfors
- Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki, Finland
| | - Shizhong Han
- Departments of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America
| | | | - Kauko Heikkilä
- Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki, Finland
| | - Ian B. Hickie
- Brain and Mind Research Institute, University of Sydney, Sydney, Australia
| | - Jouke Jan Hottenga
- Department of Biological Psychology, VU University, Amsterdam, Amsterdam, The Netherlands
| | - Pekka Jousilahti
- Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
| | - Marika Kaakinen
- Institute of Health Sciences and Biocenter Oulu, University of Oulu, Finland
| | - Mika Kähönen
- Department of Clinical Physiology, Tampere University Hospital and University of Tampere School of Medicine, Tampere, Finland
| | - Philipp D. Koellinger
- Department of Applied Economics, Erasmus Universiteit Rotterdam, Rotterdam, Netherlands
| | - Stephen Kittner
- Department of Neurology, Baltimore Veterans Affairs Medical Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
| | - Bettina Konte
- Department of Psychiatry, University of Munich (LMU), Munich, Germany
| | - Maria-Teresa Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Tiina Laatikainen
- Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
| | - Mark Leppert
- Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah, United States of America
| | - Steven M. Levy
- Department of Preventive and Community Dentistry and Department of Epidemiology, University of Iowa, Iowa City, Iowa, United States of America
| | - Rasika A. Mathias
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
| | - Daniel W. McNeil
- Department of Psychology and Dental Practice and Rural Health, West Virginia University, Morgantown, West Virginia, United States of America
| | - Sarah E. Medland
- Department of Epidemiology, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
| | - Grant W. Montgomery
- Department of Epidemiology, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
| | - Tanda Murray
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
| | - Matthias Nauck
- University Medicine Greifswald, University of Greifswald, Greifswald, Germany
| | - Kari E. North
- Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, United States of America
| | - Peter D. Paré
- Department of Medicine, University of British Columbia, Vancouver, Canada
| | - Michele Pergadia
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Ingo Ruczinski
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
| | - Veikko Salomaa
- Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
| | - Jorma Viikari
- Department of Medicine, Turku University Hospital, Turku, Finland
| | - Gonneke Willemsen
- Department of Biological Psychology, VU University, Amsterdam, Amsterdam, The Netherlands
| | - Kathleen C. Barnes
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
| | - Eric Boerwinkle
- Human Genetics Center, The University of Texas Health Science Center at Houston, Houston, Texas, United States of America
| | - Dorret I. Boomsma
- Department of Biological Psychology, VU University, Amsterdam, Amsterdam, The Netherlands
| | - Neil Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Howard J. Edenberg
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
| | - Clyde Francks
- Department of the MPI Psycholinguistics, Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands
| | - Joel Gelernter
- Departments of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America
| | - Hans Jörgen Grabe
- University Medicine Greifswald, University of Greifswald, Greifswald, Germany
| | - Hyman Hops
- Oregon Research Institute, Eugene, Oregon, United States of America
| | - Marjo-Riitta Jarvelin
- Department of Epidemiology and Biostatistics, MRC Health Protection Agency (HPA) Centre for Environment and Health School of Public Health, Imperial College London, United Kingdom; Institute of Health Sciences and Biocenter Oulu, University of Oulu, Finland; Unit of Primary Care, Oulu University Hospital, Oulu, Finland; Department of Children and Young People and Families, National Institute for Health and Welfare, Oulu, Finland
| | - Magnus Johannesson
- Department of Economics, Stockholm School of Economics, Stockholm, Sweden
| | - Kenneth S. Kendler
- Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States of America
| | - Terho Lehtimäki
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere University Hospital and University of Tampere School of Medicine, Tampere, Finland
| | - Patrik K.E. Magnusson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Mary L. Marazita
- Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| | - Jonathan Marchini
- Department of Statistics, University of Oxford, Oxford, United Kingdom
| | - Braxton D. Mitchell
- Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland, United States of America
| | - Markus M. Nöthen
- Department of Genomics, Life and Brain Center, Life and Brain Center, Institute of Human Genetics, University of Bonn, Bonn, Germany
| | - Brenda W. Penninx
- Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands
| | - Olli Raitakari
- Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital; Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland
| | - Marcella Rietschel
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Clinical Faculty Mannheim / Heidelberg University, Mannheim, Germany
| | - Dan Rujescu
- Department of Psychiatry, University of Munich (LMU), Munich, Germany
| | - Nilesh J. Samani
- Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom
| | - Ann G. Schwartz
- Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States of America
| | - Sanjay Shete
- Department of Epidemiology, MD Anderson, Houston, Texas, United States of America
| | - Margaret Spitz
- Department of Epidemiology, MD Anderson, Houston, Texas, United States of America
| | - Gary E. Swan
- Center for Health Sciences, SRI International, Menlo Park, California, United States of America
| | - Henry Völzke
- University Medicine Greifswald, University of Greifswald, Greifswald, Germany
| | - Juha Veijola
- Institute of Health Sciences and Biocenter Oulu, University of Oulu, Finland
| | - Qingyi Wei
- Department of Epidemiology, MD Anderson, Houston, Texas, United States of America
| | - Chris Amos
- Department of Epidemiology, MD Anderson, Houston, Texas, United States of America
| | - Dale S. Cannon
- Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah, United States of America
| | - Richard Grucza
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Dorothy Hatsukami
- Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Andrew Heath
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Eric O. Johnson
- Department of Behavioral Health Epidemiology, RTI International, Research Triangle Park, North Carolina, United States of America
| | - Jaakko Kaprio
- Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki, Finland
| | - Pamela Madden
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Nicholas G. Martin
- Department of Epidemiology, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
| | - Victoria L. Stevens
- Department of Epidemiology Research, American Cancer Society, Atlanta, Georgia, United States of America
| | - Robert B. Weiss
- Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah, United States of America
| | - Peter Kraft
- Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America
| | - Laura J. Bierut
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America
| | - Marissa A. Ehringer
- Institute for Behavioral Genetics, University of Colorado, Boulder, Colorado, United States of America
| |
Collapse
|
7
|
Abstract
Arterial thrombosis is a major component of vascular disease, especially myocardial infarction (MI) and stroke. Current anti-thrombotic therapies such as warfarin and clopidogrel are effective in inhibiting cardiovascular events; however, there is great inter-individual variability in response to these medications. In recent years, it has been recognized that genetic factors play a significant role in drug response, and, subsequently, common variants in genes responsible for metabolism and drug action have been identified. These discoveries along with new diagnostic targets and therapeutic strategies hold promise for more effective individualized anti-coagulation and anti-platelet therapy.
Collapse
Affiliation(s)
- Adam S Fisch
- Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, and the Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
| | | | | | | | | |
Collapse
|
8
|
Lewis JP, Stephens SH, Horenstein RB, O'Connell JR, Ryan K, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Mitchell BD, Shuldiner AR. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost 2013; 11:1640-6. [PMID: 23809542 PMCID: PMC3773276 DOI: 10.1111/jth.12342] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2013] [Accepted: 06/04/2013] [Indexed: 11/30/2022]
Abstract
BACKGROUND Cytochrome P450 2C19 (CYP2C19) is the principal enzyme responsible for converting clopidogrel into its active metabolite, and common genetic variants have been identified, most notably CYP2C19*2 and CYP2C19*17, that are believed to alter its activity and expression, respectively. OBJECTIVE We evaluated whether the consequences of the CYP2C19*2 and CYP2C19*17 variants on clopidogrel response were independent of each other or genetically linked through linkage disequilibrium (LD). PATIENTS/METHODS We genotyped the CYP2C19*2 and CYP2C19*17 variants in 621 members of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study and evaluated the effects of these polymorphisms singly and then jointly, taking into account LD, on clopidogrel prodrug level, clopidogrel active metabolite level, and adenosine 5'-diphosphate (ADP)-stimulated platelet aggregation before and after clopidogrel exposure. RESULTS The CYP2C19*2 and CYP2C19*17 variants were in LD (|D'| = 1.0; r(2) = 0.07). In association analyses that did and did not account for the effects of CYP2C19*17, CYP2C19*2 was strongly associated with levels of clopidogrel active metabolite (β = -5.24, P = 3.0 × 10(-9) and β = -5.36, P = 3.3 × 10(-14) , respectively) and posttreatment ADP-stimulated platelet aggregation (β = 7.55, P = 2.9 × 10(-16) and β = 7.51, P = 7.0 × 10(-15) , respectively). In contrast, CYP2C19*17 was marginally associated with clopidogrel active metabolite levels and ADP-stimulated platelet aggregation before (β = 1.57, P = 0.04 and β = -1.98, P = 0.01, respectively) but not after (β = 0.40, P = 0.59 and β = -0.13, P = 0.69, respectively) adjustment for the CYP2C19*2 variant. Stratified analyses of CYP2C19*2/CYP2C19*17 genotype combinations revealed that CYP2C19*2, and not CYP2C19*17, was the primary determinant in altering clopidogrel response. CONCLUSIONS Our results suggest that CYP2C19*17 has a small (if any) effect on clopidogrel-related traits and that the observed effect of this variant is due to LD with the CYP2C19*2 loss-of-function variant.
Collapse
Affiliation(s)
- J P Lewis
- Division of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Raheja UK, Stephens SH, Mitchell BD, Rohan KJ, Vaswani D, Balis TG, Nijjar GV, Sleemi A, Pollin TI, Ryan K, Reeves GM, Weitzel N, Morrissey M, Yousufi H, Langenberg P, Shuldiner AR, Postolache TT. Seasonality of mood and behavior in the Old Order Amish. J Affect Disord 2013; 147:112-7. [PMID: 23164460 PMCID: PMC3606685 DOI: 10.1016/j.jad.2012.10.019] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2012] [Accepted: 10/23/2012] [Indexed: 11/18/2022]
Abstract
BACKGROUND/OBJECTIVE We examined seasonality and winter seasonal affective disorder (SAD) in the Old Order Amish of Lancaster County, Pennsylvania, a unique population that prohibits use of network electric light in their homes. METHODS We estimated SAD using the seasonal pattern assessment questionnaire (SPAQ) in 1306 Amish adults and compared the frequencies of SAD and total SAD (i.e., presence of either SAD or subsyndromal-SAD) between men and women, young and old, and awareness of (ever vs. never heard about) SAD. Heritability of global seasonality score (GSS) was estimated using the maximum likelihood method, including a household effect to capture shared environmental effects. RESULTS The mean (±SD) GSS was 4.36 (±3.38). Prevalence was 0.84% (95% CI: 0.36-1.58) for SAD and 2.59% (95% CI: 1.69-3.73) for total SAD. Heritability of GSS was 0.14±0.06 (SE) (p=0.002) after adjusting for age, gender, and household effects. LIMITATIONS Limitations include likely overestimation of the rates of SAD by SPAQ, possible selection bias and recall bias, and limited generalizability of the study. CONCLUSIONS In the Amish, GSS and SAD prevalence were lower than observed in earlier SPAQ-based studies in other predominantly Caucasian populations. Low heritability of SAD suggests dominant environmental effects. The effects of awareness, age and gender on SAD risk were similar as in previous studies. Identifying factors of resilience to SAD in the face of seasonal changes in the Amish could suggest novel preventative and therapeutic approaches to reduce the impact of SAD in the general population.
Collapse
Affiliation(s)
- Uttam K Raheja
- Mood and Anxiety Program, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Hartz SM, Short SE, Saccone NL, Culverhouse R, Chen L, Schwantes-An TH, Coon H, Han Y, Stephens SH, Sun J, Chen X, Ducci F, Dueker N, Franceschini N, Frank J, Geller F, Gubjartsson D, Hansel NN, Jiang C, Keskitalo-Vuokko K, Liu Z, Lyytikäinen LP, Michel M, Rawal R, Rosenberger A, Scheet P, Shaffer JR, Teumer A, Thompson JR, Vink JM, Vogelzangs N, Wenzlaff AS, Wheeler W, Xiao X, Yang BZ, Aggen SH, Balmforth AJ, Baumeister SE, Beaty T, Bennett S, Bergen AW, Boyd HA, Broms U, Campbell H, Chatterjee N, Chen J, Cheng YC, Cichon S, Couper D, Cucca F, Dick DM, Foroud T, Furberg H, Giegling I, Gu F, Hall AS, Hällfors J, Han S, Hartmann AM, Hayward C, Heikkilä K, Hewitt JK, Hottenga JJ, Jensen MK, Jousilahti P, Kaakinen M, Kittner SJ, Konte B, Korhonen T, Landi MT, Laatikainen T, Leppert M, Levy SM, Mathias RA, McNeil DW, Medland SE, Montgomery GW, Muley T, Murray T, Nauck M, North K, Pergadia M, Polasek O, Ramos EM, Ripatti S, Risch A, Ruczinski I, Rudan I, Salomaa V, Schlessinger D, Styrkársdóttir U, Terracciano A, Uda M, Willemsen G, Wu X, Abecasis G, Barnes K, Bickeböller H, Boerwinkle E, Boomsma DI, Caporaso N, Duan J, Edenberg HJ, Francks C, Gejman PV, Gelernter J, Grabe HJ, Hops H, Jarvelin MR, Viikari J, Kähönen M, Kendler KS, Lehtimäki T, Levinson DF, Marazita ML, Marchini J, Melbye M, Mitchell BD, Murray JC, Nöthen MM, Penninx BW, Raitakari O, Rietschel M, Rujescu D, Samani NJ, Sanders AR, Schwartz AG, Shete S, Shi J, Spitz M, Stefansson K, Swan GE, Thorgeirsson T, Völzke H, Wei Q, Wichmann HE, Amos CI, Breslau N, Cannon DS, Ehringer M, Grucza R, Hatsukami D, Heath A, Johnson EO, Kaprio J, Madden P, Martin NG, Stevens VL, Stitzel JA, Weiss RB, Kraft P, Bierut LJ. Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. ACTA ACUST UNITED AC 2012; 69:854-60. [PMID: 22868939 DOI: 10.1001/archgenpsychiatry.2012.124] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
CONTEXT Recent studies have shown an association between cigarettes per day (CPD) and a nonsynonymous single-nucleotide polymorphism in CHRNA5, rs16969968. OBJECTIVE To determine whether the association between rs16969968 and smoking is modified by age at onset of regular smoking. DATA SOURCES Primary data. STUDY SELECTION Available genetic studies containing measures of CPD and the genotype of rs16969968 or its proxy. DATA EXTRACTION Uniform statistical analysis scripts were run locally. Starting with 94,050 ever-smokers from 43 studies, we extracted the heavy smokers (CPD >20) and light smokers (CPD ≤10) with age-at-onset information, reducing the sample size to 33,348. Each study was stratified into early-onset smokers (age at onset ≤16 years) and late-onset smokers (age at onset >16 years), and a logistic regression of heavy vs light smoking with the rs16969968 genotype was computed for each stratum. Meta-analysis was performed within each age-at-onset stratum. DATA SYNTHESIS Individuals with 1 risk allele at rs16969968 who were early-onset smokers were significantly more likely to be heavy smokers in adulthood (odds ratio [OR] = 1.45; 95% CI, 1.36-1.55; n = 13,843) than were carriers of the risk allele who were late-onset smokers (OR = 1.27; 95% CI, 1.21-1.33, n = 19,505) (P = .01). CONCLUSION These results highlight an increased genetic vulnerability to smoking in early-onset smokers.
Collapse
Affiliation(s)
- Sarah M Hartz
- Washington University School of Medicine, St Louis, Missouri, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Stephens SH, Hoft NR, Schlaepfer IR, Young SE, Corley RC, McQueen MB, Hopfer C, Crowley T, Stallings M, Hewitt J, Ehringer MA. Externalizing behaviors are associated with SNPs in the CHRNA5/CHRNA3/CHRNB4 gene cluster. Behav Genet 2012; 42:402-14. [PMID: 22042234 PMCID: PMC3506120 DOI: 10.1007/s10519-011-9514-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2011] [Accepted: 10/17/2011] [Indexed: 10/16/2022]
Abstract
There is strong evidence for shared genetic factors contributing to childhood externalizing disorders and substance abuse. Externalizing disorders often precede early substance experimentation, leading to the idea that individuals inherit a genetic vulnerability to generalized disinhibitory psychopathology. Genetic variation in the CHRNA5/CHRNA3/CHRNB4 gene cluster has been associated with early substance experimentation, nicotine dependence, and other drug behaviors. This study examines whether the CHRNA5/CHRNA3/CHRNB4 locus is correlated also with externalizing behaviors in three independent longitudinally assessed adolescent samples. We developed a common externalizing behavior phenotype from the available measures in the three samples, and tested for association with 10 SNPs in the gene cluster. Significant results were detected in two of the samples, including rs8040868, which remained significant after controlling for smoking quantity. These results expand on previous work focused mainly on drug behaviors, and support the hypothesis that variation in the CHRNA5/CHRNA3/CHRNB4 locus is associated with early externalizing behaviors.
Collapse
Affiliation(s)
- Sarah H. Stephens
- Departments of Integrative Physiology, University of Colorado Boulder
- Institute for Behavioral Genetics, University of Colorado Boulder
| | - Nicole R. Hoft
- Institute for Behavioral Genetics, University of Colorado Boulder
| | - Isabel R. Schlaepfer
- Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Denver
| | - Susan E. Young
- Institute for Behavioral Genetics, University of Colorado Boulder
| | - Robin C. Corley
- Institute for Behavioral Genetics, University of Colorado Boulder
| | - Matthew B. McQueen
- Departments of Integrative Physiology, University of Colorado Boulder
- Institute for Behavioral Genetics, University of Colorado Boulder
| | | | - Thomas Crowley
- Departments of Psychiatry, University of Colorado Denver
| | - Michael Stallings
- Departments of Psychology, University of Colorado Boulder
- Departments of Neuroscience, University of Colorado Boulder
- Institute for Behavioral Genetics, University of Colorado Boulder
| | - John Hewitt
- Departments of Psychology, University of Colorado Boulder
- Institute for Behavioral Genetics, University of Colorado Boulder
| | - Marissa A. Ehringer
- Departments of Integrative Physiology, University of Colorado Boulder
- Institute for Behavioral Genetics, University of Colorado Boulder
| |
Collapse
|
12
|
Lubke GH, Stephens SH, Lessem JM, Hewitt JK, Ehringer MA. The CHRNA5/A3/B4 gene cluster and tobacco, alcohol, cannabis, inhalants and other substance use initiation: replication and new findings using mixture analyses. Behav Genet 2012; 42:636-46. [PMID: 22382757 DOI: 10.1007/s10519-012-9529-y] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2011] [Accepted: 01/30/2012] [Indexed: 11/28/2022]
Abstract
Multiple studies have provided evidence for genetic associations between single nucleotide polymorphisms (SNPs) located on the CHRNA5/A3/B4 gene cluster and various phenotypes related to Nicotine Dependence (Greenbaum et al. 2009). Only a few studies have investigated other substances of abuse. The current study has two aims, (1) to extend previous findings by focusing on associations between the CHRNA5/A3/B4 gene cluster and age of initiation of several different substances, and (2) to investigate heterogeneity in age of initiation across the different substances. All analyses were conducted with a subset of the Add Health study with available genetic data. The first aim was met by modeling onset of tobacco, alcohol, cannabis, inhalants, and other substance use using survival mixture analysis (SMA). Ten SNPs in CHRNA5/A3/B4 were used to predict phenotypic differences in the risk of onset, and differences between users and non-users. The survival models aim at investigating differences in the risk of initiation across the 5-18 age range for each phenotype separately. Significant or marginally significant genetic effects were found for all phenotypes. The genetic effects were mainly related to the risk of initiation and to a lesser extent to discriminating between users and non-users. To address the second goal, the survival analyses were complemented by a latent class analysis that modeled all phenotypes jointly. One of the ten SNPs was found to predict differences between the early and late onset classes. Taken together, our study provides evidence for a general role of the CHRNA5/A3/B4 gene cluster in substance use initiation that is not limited to nicotine and alcohol.
Collapse
Affiliation(s)
- Gitta H Lubke
- Department of Psychology, University of Notre Dame, 118 Haggar Hall, Notre Dame, IN 46556, USA.
| | | | | | | | | |
Collapse
|
13
|
Stephens SH, Franks A, Berger R, Palionyte M, Fingerlin TE, Wagner B, Logel J, Olincy A, Ross RG, Freedman R, Leonard S. Multiple genes in the 15q13-q14 chromosomal region are associated with schizophrenia. Psychiatr Genet 2012; 22:1-14. [PMID: 21970977 PMCID: PMC3878876 DOI: 10.1097/ypg.0b013e32834c0c33] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE The chromosomal region, 15q13-q14, including the α7 nicotinic acetylcholine receptor gene, CHRNA7, is a replicated region for schizophrenia. This study fine-mapped genes at 15q13-q14 to determine whether the association is unique to CHRNA7. METHODS Family-based and case-control association studies were performed on Caucasian-non-Hispanic and African-American individuals from 120 families as well as 468 individual patients with schizophrenia and 144 well-characterized controls. Single-nucleotide polymorphism (SNP) markers were genotyped, and association analyses carried out for the outcomes of schizophrenia, smoking, and smoking in schizophrenia. RESULTS Three genes were associated with schizophrenia in both ethnic populations: TRPM1, KLF13, and RYR3. Two SNPs in CHRNA7 were associated with schizophrenia in African-Americans, and a second SNP in CHRNA7 was significant for an association with smoking and smoking in schizophrenia in Caucasians. CONCLUSION Results of these studies support association of the 15q13-q14 region with schizophrenia. The broad positive association suggests that more than one 15q gene may be contributing to the disorder, either in combination or through a regulatory mechanism.
Collapse
Affiliation(s)
- Sarah H. Stephens
- Department of Psychiatry, University of Colorado Denver, Denver, Colorado, USA
| | - Alexis Franks
- Department of Psychiatry, University of Colorado Denver, Denver, Colorado, USA
| | - Ralph Berger
- Department of Psychiatry, University of Colorado Denver, Denver, Colorado, USA
| | - Milda Palionyte
- Department of Psychiatry, University of Colorado Denver, Denver, Colorado, USA
| | - Tasha E. Fingerlin
- Preventive Medicine and Biometrics, University of Colorado Denver, Denver, Colorado, USA
| | - Brandie Wagner
- Preventive Medicine and Biometrics, University of Colorado Denver, Denver, Colorado, USA
| | - Judith Logel
- Department of Psychiatry, University of Colorado Denver, Denver, Colorado, USA
| | - Ann Olincy
- Department of Psychiatry, University of Colorado Denver, Denver, Colorado, USA
| | - Randal G. Ross
- Department of Psychiatry, University of Colorado Denver, Denver, Colorado, USA
| | - Robert Freedman
- Department of Psychiatry, University of Colorado Denver, Denver, Colorado, USA
- Veterans Affairs Medical Research Center, Denver, Colorado, USA
| | - Sherry Leonard
- Department of Psychiatry, University of Colorado Denver, Denver, Colorado, USA
- Veterans Affairs Medical Research Center, Denver, Colorado, USA
| |
Collapse
|
14
|
Dai N, Foldager L, Gallego JA, Hack LM, Ji Y, Lett TA, Liu BC, Loken EK, Mandelli L, Mehta D, Power RA, Sprooten E, Stephens SH, Paska AV, Yan J, Zai CC, Zai G, Zhang-James Y, O’Shea A, DeLisi LE. Summaries from the XIX World Congress of Psychiatric Genetics, Washington, DC, September 10-14, 2011. Am J Med Genet B Neuropsychiatr Genet 2012; 159B:128-9. [PMID: 22180335 PMCID: PMC4416401 DOI: 10.1002/ajmg.b.32017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Nan Dai
- School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Western Australian Institute for Medical Research, Perth, Australia
| | - Leslie Foldager
- Center for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark,Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark
| | - Juan A. Gallego
- The Zucker Hillside Hospital, Glen Oaks, New York,The Feinstein Institute for Medical Research, Manhasset, New York
| | - Laura M. Hack
- Department of Human and Molecular Genetics, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia
| | - Yuan Ji
- Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota
| | | | - Bao-Cheng Liu
- Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China
| | - Erik K. Loken
- Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia
| | - Laura Mandelli
- Institute of Psychiatry “P. Ottonello”, University of Bologna, Bologna, Italy
| | - Divya Mehta
- Max Planck Institute of Psychiatry, Munich, Germany
| | - Robert A. Power
- Social Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, De Crespigny Park, London, United Kingdom
| | - Emma Sprooten
- Division of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom
| | - Sarah H. Stephens
- Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland
| | - Alja Videtic Paska
- Faculty of Medicine, Institute of Biochemistry, University of Ljubljana, Ljubljana, Slovenia
| | - Jia Yan
- Department of Human and Molecular Genetics, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia
| | - Clement C. Zai
- Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
| | - Gwyneth Zai
- Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
| | - Yanli Zhang-James
- Departments of Psychiatry. SUNY Upstate Medical University, Syracuse, New York
| | - Anne O’Shea
- Harvard Medical School, Boston, Massachusetts
| | - Lynn E. DeLisi
- VA Boston Healthcare System, Brockton, Massachusetts,Correspondence to: Lynn E. DeLisi, M.D., Boston Healthcare System, 940 Belmont Street, Brockton, MA 02301.
| |
Collapse
|
15
|
Abstract
Evolutionary genetic models predict that the cumulative effect of rare deleterious mutations across the genome—known as mutational load burden—increases the susceptibility to complex disease. To test the mutational load burden hypothesis, we adopted a two-tiered approach: assessing the impact of whole-exome minor allele load burden and then conducting individual-gene screening. For our primary analysis, we examined various minor allele frequency (MAF) thresholds and weighting schemes to examine the overall effect of minor allele load on affection status. We found a consistent association between minor allele load and affection status, but this effect did not markedly increase within rare and/or functional single-nucleotide polymorphisms (SNPs). Our follow-up analysis considered minor allele load in individual genes to see whether only one or a few genes were driving the overall effect. Examining our most significant result—minor allele load of nonsynonymous SNPs with MAF < 2.4%—we detected no significantly associated genes after Bonferroni correction for multiple testing. After moderately significant genes (p < 0.05) were removed, the overall effect of rare nonsynonymous allele load remained significant. Overall, we did not find clear support for mutational load burden on affection status; however, these results are ultimately dependent on and limited by the nature of the Genetic Analysis Workshop 17 simulation.
Collapse
Affiliation(s)
- Daniel P Howrigan
- Institute for Behavioral Genetics, University of Colorado at Boulder, 1480 30th Street, Boulder, CO 80303, USA.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Stephens SH, Logel J, Barton A, Franks A, Schultz J, Short M, Dickenson J, James B, Fingerlin TE, Wagner B, Hodgkinson C, Graw S, Ross RG, Freedman R, Leonard S. Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophr Res 2009; 109:102-12. [PMID: 19181484 PMCID: PMC2748327 DOI: 10.1016/j.schres.2008.12.017] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2008] [Revised: 12/08/2008] [Accepted: 12/12/2008] [Indexed: 12/30/2022]
Abstract
BACKGROUND The alpha7 neuronal nicotinic acetylcholine receptor subunit gene (CHRNA7) is localized in a chromosomal region (15q14) linked to schizophrenia in multiple independent studies. CHRNA7 was selected as the best candidate gene in the region for a well-documented endophenotype of schizophrenia, the P50 sensory processing deficit, by genetic linkage and biochemical studies. METHODS Subjects included Caucasian-Non Hispanic and African-American case-control subjects collected in Denver, and schizophrenic subjects from families in the NIMH Genetics Initiative on Schizophrenia. Thirty-five single nucleotide polymorphisms (SNPs) in the 5'-upstream regulatory region of CHRNA7 were genotyped for association with schizophrenia, and for smoking in schizophrenia. RESULTS The rs3087454 SNP, located at position -1831 bp in the upstream regulatory region of CHRNA7, was significantly associated with schizophrenia in the case-control samples after multiple-testing correction (P=0.0009, African American; P=0.013, Caucasian-Non Hispanic); the association was supported in family members. There was nominal association of this SNP with smoking in schizophrenia. CONCLUSIONS The data support association of regulatory region polymorphisms in the CHRNA7 gene with schizophrenia.
Collapse
Affiliation(s)
- Sarah H. Stephens
- Department of Psychiatry, University of Colorado at Denver, United States
| | - Judith Logel
- Department of Psychiatry, University of Colorado at Denver, United States
| | - Amanda Barton
- Department of Psychiatry, University of Colorado at Denver, United States
| | - Alexis Franks
- Department of Psychiatry, University of Colorado at Denver, United States
| | - Jessica Schultz
- Department of Psychiatry, University of Colorado at Denver, United States
| | - Margaret Short
- Department of Psychiatry, University of Colorado at Denver, United States
| | - Jane Dickenson
- Department of Psychiatry, University of Colorado at Denver, United States
| | - Benjamin James
- Department of Psychiatry, University of Colorado at Denver, United States
| | - Tasha E. Fingerlin
- Department of Preventive Medicine and Biometrics, University of Colorado at Denver, United States
| | - Brandie Wagner
- Department of Preventive Medicine and Biometrics, University of Colorado at Denver, United States
| | | | - Sharon Graw
- Department of Psychiatry, University of Colorado at Denver, United States
| | - Randal G. Ross
- Department of Psychiatry, University of Colorado at Denver, United States
| | - Robert Freedman
- Department of Psychiatry, University of Colorado at Denver, United States, The Veterans Affairs Medical Research Center, Denver, Colorado 80045, United States
| | - Sherry Leonard
- Department of Psychiatry, University of Colorado at Denver, United States, The Veterans Affairs Medical Research Center, Denver, Colorado 80045, United States,Corresponding author. Department of Psychiatry University of Colorado at Denver, Mailstop 8344, P.O. Box 6511, Aurora, CO 80045, United States. Tel.: +1 303 724 4426; fax: +1 303 724 4425. (S. Leonard)
| |
Collapse
|
17
|
Krininger CE, Stephens SH, Hansen PJ. Developmental changes in inhibitory effects of arsenic and heat shock on growth of pre-implantation bovine embryos. Mol Reprod Dev 2002; 63:335-40. [PMID: 12237949 DOI: 10.1002/mrd.90017] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Although sensitive to various disrupters, pre-implantation embryos possess some cellular cytoprotective mechanisms that allow continued survival in the face of a deleterious environment. For stresses such as heat shock, embryonic resistance increases as development proceeds. Present objectives were to determine whether (1) arsenic compromises development of pre-implantation bovine embryos, (2) developmental changes in embryonic resistance to arsenic mimic those seen for resistance to heat shock, and (3) developmental patterns in induction of apoptosis by arsenic are correlated with similar changes in resistance of embryos to inhibitory effects of arsenic on development. Bovine embryos produced by in vitro fertilization were exposed at the two-cell stage or at day 5 after insemination (embryos > or = 16-cells in number) to either sodium arsenite (0, 1, 5, or 10 microM) or heat shock (exposure to 41 degrees C for 0, 3, 4.5, 6, or 9 hr). Arsenic induced apoptosis and increased group 2 caspase activity for embryos at the > or = 16-cell stage, but not for embryos at the two-cell stage. In contrast to these developmental changes in apoptosis responses, exposure to arsenic reduced cell number 24 hr after exposure for both two-cell embryos and embryos > or = 16-cells. Similarly, the percentage of embryos that developed to the blastocyst stage at day 8 after fertilization was reduced by arsenic exposure at both stages of development. Heat shock, conversely, reduced development to the blastocyst stage when applied at the two-cell stage, but not when applied to embryos > or = 16-cells at day 5 after insemination. In conclusion, arsenic can compromise development of bovine pre-implantation embryos, the temporal window of sensitivity of embryos to arsenic is wider than for heat shock, and cellular cytoprotective responses that embryos acquire for thermal resistance are not sufficient to cause increased embryonic resistance to arsenic exposure. It is likely that despite common cellular pathologies caused by arsenic and heat shock, arsenic acts to reduce development in part through biochemical pathways not activated by heat shock. Moreover, the embryo does not acquire significant resistance to these perturbations within the time frame in development examined.
Collapse
Affiliation(s)
- C E Krininger
- Department of Animal Sciences, University of Florida, Gainesville, Florida, USA
| | | | | |
Collapse
|
18
|
Stephens SH, Silvey VL, Wheeler RH. A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin. Cancer 1990; 66:443-6. [PMID: 2194642 DOI: 10.1002/1097-0142(19900801)66:3<443::aid-cncr2820660307>3.0.co;2-k] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Thirty-seven patients with advanced incurable malignancies who were receiving their first course of cisplatin (greater than or equal to 90 mg/m2 bolus), alone or in combination with other antineoplastic agents, were entered in this randomized, double-blind study to determine the antiemetic efficacy of the addition of high-dose dexamethasone to lorazepam plus metoclopramide. All patients received lorazepam (1.5 mg/m2) and metoclopramide (2.0 mg/kg) intravenously (IV) 30 minutes before cisplatin, with the same dose of metoclopramide repeated 1.5, 3.5, 6.5, and 9.5 hours after the 30-minute cisplatin infusion. Patients were randomized to receive dexamethasone (0.5 mg/kg) or placebo by slow bolus injection 30 minutes before cisplatin. All patients were hospitalized for 24 hours and evaluated by observation after cisplatin and a patient questionnaire before discharge. Eighteen patients received metoclopramide and lorazepam without dexamethasone: six (33%) reported no vomiting and four (22%) reported no nausea or vomiting. Nineteen patients also received dexamethasone: 14 (74%) had no vomiting and 13 (68%) reported no nausea or vomiting. These differences were statistically significantly different (P = 0.013 and 0.005, respectively). The side effects attributable to the antiemetic regimen were somnolence (100%), confusion (8%), and diarrhea (46%), and were the same in both arms. Dexamethasone significantly improved the antiemetic efficacy of metoclopramide plus lorazepam without adding toxicity. This three-drug combination gave a high rate of control of acute emesis induced by high-dose cisplatin.
Collapse
Affiliation(s)
- S H Stephens
- Department of Medicine, University of Alabama, Birmingham 35294
| | | | | |
Collapse
|